Last reviewed · How we verify
NCT03802292
First-In-Man, Healthy Volunteer Study to Evaluate Safety on the Use of YQ23
Phase 1 trial testing YQ23 in Healthy Volunteers in 58 participants. Completed in 20 November 2020.
20 September 2020
Quick facts
| Lead sponsor | New Beta Innovation Limited |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | single |
| Primary purpose | other |
| Enrollment | 58 |
| Start date | 16 January 2019 |
| Primary completion | 20 September 2020 |
| Estimated completion | 20 November 2020 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- YQ23 — full drug profile →
- Matching Placebo — full drug profile →
Conditions studied
- Healthy Volunteers — all drugs for Healthy Volunteers →
Sponsor
New Beta Innovation Limited — full company profile →
Who can join
Adults 18 to 50, any sex, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is to test the safety, tolerability, pharmacokinetics (PK-the amount of study drug in the blood), and immunogenicity (how the study drug affects the immune system) of single dose and dose levels of an investigational drug called YQ23.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03802292
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of YQ23
Trials testing the same drug.
- NCT04792008 — YQ23 Study in Patients With Critical Limb Ischaemia · Phase 1, PHASE2 · terminated
- NCT04513067 — A Safety Study of YQ23 in Advanced Solid Tumors Patients · Phase 1 · terminated
Other recruiting trials for Healthy Volunteers
Currently open trials in the same condition.
- NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
- NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
- NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
- NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
- NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting
Other New Beta Innovation Limited trials
Trials by the same sponsor.
- NCT04792008 — YQ23 Study in Patients With Critical Limb Ischaemia · Phase 1, PHASE2 · terminated
- NCT04513067 — A Safety Study of YQ23 in Advanced Solid Tumors Patients · Phase 1 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03802292 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by New Beta Innovation Limited
- Last refreshed: 3 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03802292.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing